News
Featured News
Elixirgen Scientific Achieves ISO 9001 Certification, Strengthening Commitment to Excellence in Biotechnology
March 12, 2024
Baltimore, Maryland, USA (March 12, 2024) – Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited for ISO 9001:2015 certification. The certification is an internationally recognized standard developed by the International Organization for Standardization (ISO) that ensures a company’s [...]
Featured News
Elixirgen Scientific Japan Awarded Top 10 CDMOs in APAC 2023
December 01, 2023
Fujisawa, Japan (December 07, 2023) – Elixirgen Scientific Japan, Inc (EsJ), a Japanese provider of synthetic mRNA contract development and manufacturing services, was awarded TOP 10 CDMOs in APAC - 2023 by Pharma Tech Outlook. Recognized for its excellence in delivering innovative and high-quality solutions in mRNA manufacturing, EsJ has demonstrated significant advancements in this [...]
Featured News
Research achievement using iPSC-derived neurons published in the American scientific journal, iScience
March 30, 2023
A joint research of Ricoh and the University of Tokyo TOKYO, March 27, 2023 – Ricoh's research group at the Biomedical R&D Department, led by Waka Lin, and Yuko Sekino, Project Professor at the Graduate School of Agriculture and Life Sciences, the University of Tokyo, have jointly demonstrated that transcription factor-induced human iPSC-derived neurons reach functional [...]
All News
Filter By Year
TriLink BioTechnologies® Signs Non-exclusive License and Supply Agreement with Elixirgen Scientific Japan for CleanCap® mRNA capping technology
September 26, 2023
TriLink CleanCap® mRNA capping technology now accessible to ESJ customers for non-commercial use FUJISAWA (SEPTEMBER 26, 2023) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology with Elixirgen Scientific Japan, Inc […]
Ricoh to strengthen support for drug discovery services using mRNA. Agreement reached with Elixirgen Scientific, a biotechnology company, to acquire additional shares
May 17, 2022
TOKYO, May 17, 2022 – Ricoh Company, Ltd. and Elixirgen Scientific, Inc. (Baltimore, Maryland, USA) announce that they have agreed and signed a contract for Ricoh to acquire a majority stake in Elixirgen Scientific. Ricoh had previously acquired 34.5% of Elixirgen Scientific’s stock in 2019. By having Elixirgen Scientific as its subsidiary, Ricoh aims to […]
Sales Partnership with Swift Scientific
April 8, 2022
We are excited to announce that Swift Scientific will now be Elixirgen Scientific’s sales representative in the Northeastern US territory. Together we anticipate business expansion with wider support in the region to better serve our valued clients. Visit Swift Scientific website here.
Product Launch: Quick-Neuron™ Precursor – mRNA Kit (Small)
August 11, 2021
Quick-Neuron™ Precursor differentiated cell cultures continue to proliferate and express a variety of NPC markers, such as nestin (NES), vimentin (VIM), Hes Family BHLH Transcription Factor 5 (HES5), SRY-Box Transcription Factor 1 (SOX1), and SRY-Box Transcription Factor 2 (SOX2). Differentiation achieved in just 6 days Proprietary transcription factor-based stem cell differentiation No genetic footprint Viable […]
Product Launch: Quick-Neuron™ Sensory – mRNA Kit (Small)
June 16, 2021
Our Quick-Neuron™ Sensory differentiated cell cultures display typical neurite outgrowth and express a variety of neuronal markers, such as tubulin beta 3 class III (TUBB3) and variety of sensory neuron markers such as peripherin (PRPH), islet-1 (ISL1), and brain-specific homeobox/POU domain protein 3A (BRN3A/POU4F1). • Differentiation achieved in just 10 days • Proprietary transcription factor-based […]
Product Launch: Quick-Neuron™ Precursor-Human iPSC-derived Neural Precursor Cells
April 29, 2021
Our Quick-Neuron™ Precursor – Human iPSC-derived Neural Precursor Cells (NPCs) proliferate and express a variety of NPC markers, such as neuroectodermal stem cell marker, Nestin (NES) and Vimentin (VIM). • Available from multiple healthy and patient iPSC lines • Proprietary transcription factor-based stem cell differentiation • No genetic footprint • Viable long-term • Suitable for […]
